Huadong Pharmaceutical announced that the National Health Insurance Administration and the Ministry of Human Resources and Social Affairs issued a new version of the drug catalogue and the commercial insurance innovative drug catalogue, and some of the company's products and cooperative products were included. The wholly-owned subsidiary, Huadong Huadong usinumab injections were adjusted to regular catalogue management, and the scope of payment was changed; the cooperative products Senapalil capsules and linalacene glutarate capsules were included in the negotiated drug section during the agreement period, and Zevokiolensis injections were included in the commercial insurance innovative drug catalogue. The new drug catalogue will be implemented in 2026. The inclusion of the above products has no significant impact on recent performance and is expected to help future market promotion.

Huadong Pharmaceutical announced that the National Health Insurance Administration and the Ministry of Human Resources and Social Affairs issued a new version of the drug catalogue and the commercial insurance innovative drug catalogue, and some of the company's products and cooperative products were included. The wholly-owned subsidiary, Huadong Huadong usinumab injections were adjusted to regular catalogue management, and the scope of payment was changed; the cooperative products Senapalil capsules and linalacene glutarate capsules were included in the negotiated drug section during the agreement period, and Zevokiolensis injections were included in the commercial insurance innovative drug catalogue. The new drug catalogue will be implemented in 2026. The inclusion of the above products has no significant impact on recent performance and is expected to help future market promotion.